Yahoo Home Exai
| Genre | Electronic , Techno , IDM , Experimental Techno , Glitch |
| Release Date | March 4, 2013 |
| Artist | Autechre |
Tracklist
- 1FleureAutechre4:52
- 2Irlite (Get 0)Autechre10:01
- 3Prac-FAutechre4:19
- 4Jatevee CAutechre4:14
- 5T Ess XiAutechre6:43
- 6VekosAutechre6:41
- 7FlepAutechre6:42
- 8TuinoriznAutechre3:40
- 9BladeloresAutechre12:21
- 1011 isAutechre7:18
- 11NodezshAutechre8:39
- 12RunrepikAutechre4:35
- 13Spl9Autechre7:06
- 14CloudlineAutechre10:12
- 15Deco LocAutechre5:27
- 16Recks OnAutechre9:21
- 17Yjy UxAutechre8:25
Apple and Apple Music are trademarks of Apple Inc., registered in the U.S. and other countries
Top Stories
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 68.03%: Read This Before Placing a Bet
- The mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 68% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
People Also Viewed
More Stories
- BusinessZacks
Wall Street Analysts Predict a 99.07% Upside in Exscientia PLC Sponsored ADR (EXAI): Here's What You Should Know
The consensus price target hints at a 99.1% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- BusinessZacks
Down -33.28% in 4 Weeks, Here's Why Exscientia PLC Sponsored ADR (EXAI) Looks Ripe for a Turnaround
Exscientia PLC Sponsored ADR (EXAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- BusinessInvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
The pharmaceutical sector generates a huge $1.2 trillion of revenue globally, and the U.S. is by far the most lucrative country for drug makers in the world. Therefore, the profits of successful American pharmaceutical firms can be truly staggering. What’s even better for investors is that pharma firms’ profit growth can really be gargantuan because some successful drugs can generate literally tens of billions of dollars of revenue. As a result, when biotech companies develop blockbuster drugs,
- BusinessInvestorPlace
3 Pharma Stocks That Will Boom Thanks to AI
A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms. The quantum leap forward in computational power that AI affords gives pharmaceutical firms the ability to develop products faster than ever before. This has lead investors to start looking for the top AI-driven pharma stocks. The intersection of data science and machine learning makes research and development fundamentally different than it was previously.
- BusinessZacks
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 63%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 62.6% in Exscientia PLC Sponsored ADR (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- BusinessBenzinga
Three Analysts Initiate Coverage On This AI-Based Pharmatech
BofA initiated coverage on Exscientia Plc (NASDAQ: EXAI) with a Buy and $27 price target, implying a 25.5% upside. Analyst Michael Ryskin believes Exscientia stands out from other tech-enabled biotechs, as it uses AI to develop better drugs in a shorter period. Ryskin adds that the company's lead compounds remain in the early Phase 1 trials as the platform validation continues. Goldman Sachs also initiated Exscientia with a Buy and $30 price target, suggesting a 39.5% upside. Analyst Chris Shibu
